Skip to content

Released Mar 7, 2024, before the open

10-K filed Mar 7, 2024, 67 days after period end · 0001628280-24-009539

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$5.77Mderived+37.9% vs Q4 2022−67.0% vs Q3 2023
Net Income-$24.11MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$25,458,000N/M
Operating Cash Flowderived-$27,541,000N/M
Free Cash Flowderived-$27,578,000N/M
Margins · derived
Operating margin-441.3%+320.8 pt vs Q4 2022
Net margin-417.9%+272.5 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020derived from reported figures
Revenue$5.77M$4.18M$713.00K$251.00K
Net Income-$24.11M-$28.89M-$29.14M-$20.76M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Foghorn Therapeutics Inc. · CIK 1822462 · Engraved from SEC EDGAR